16,499 Shares in Corcept Therapeutics Incorporated $CORT Bought by Entropy Technologies LP

Entropy Technologies LP acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT) in the first quarter, HoldingsChannel reports. The fund acquired 16,499 shares of the biotechnology company’s stock, valued at approximately $665,000.

Other hedge funds also recently bought and sold shares of the company. Torren Management LLC purchased a new stake in shares of Corcept Therapeutics during the 4th quarter worth about $25,000. Advisory Services Network LLC bought a new position in Corcept Therapeutics during the third quarter valued at approximately $25,000. Atlas Capital Advisors Inc. bought a new position in Corcept Therapeutics during the fourth quarter valued at approximately $31,000. State of Wyoming raised its position in Corcept Therapeutics by 29.5% during the first quarter. State of Wyoming now owns 816 shares of the biotechnology company’s stock valued at $33,000 after acquiring an additional 186 shares in the last quarter. Finally, Hantz Financial Services Inc. lifted its stake in Corcept Therapeutics by 113.7% in the fourth quarter. Hantz Financial Services Inc. now owns 985 shares of the biotechnology company’s stock valued at $34,000 after acquiring an additional 524 shares during the last quarter. 93.61% of the stock is owned by institutional investors and hedge funds.

Corcept Therapeutics Price Performance

Shares of CORT opened at $92.95 on Thursday. The company has a market capitalization of $9.98 billion, a PE ratio of 265.58 and a beta of 0.47. Corcept Therapeutics Incorporated has a one year low of $28.66 and a one year high of $97.63. The company’s fifty day moving average price is $82.51 and its 200 day moving average price is $55.80.

Corcept Therapeutics (NASDAQ:CORT) last issued its quarterly earnings results on Wednesday, July 29th. The biotechnology company reported $0.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.02 by $0.34. The company had revenue of $256.15 million for the quarter, compared to the consensus estimate of $221.15 million. Corcept Therapeutics had a return on equity of 7.40% and a net margin of 6.14%.The firm’s revenue was up 31.7% compared to the same quarter last year. During the same period last year, the business posted $0.29 earnings per share. Analysts anticipate that Corcept Therapeutics Incorporated will post 0.53 earnings per share for the current year.

Insider Activity

In related news, Director David L. Mahoney sold 20,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The stock was sold at an average price of $84.53, for a total transaction of $1,690,600.00. Following the completion of the sale, the director owned 26,147 shares in the company, valued at $2,210,205.91. This represents a 43.34% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, insider William Guyer sold 20,000 shares of the firm’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $93.13, for a total value of $1,862,600.00. Following the completion of the sale, the insider directly owned 3,985 shares in the company, valued at $371,123.05. This trade represents a 83.39% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 300,000 shares of company stock worth $22,088,050 over the last 90 days. Company insiders own 20.70% of the company’s stock.

Corcept Therapeutics News Roundup

Here are the key news stories impacting Corcept Therapeutics this week:

• Positive Sentiment: Quarterly results exceeded expectations. Second-quarter revenue increased 31.7% year over year to $256.1 million, ahead of the roughly $221 million consensus. Adjusted earnings were $0.36 per share, substantially above estimates ranging from a $0.04 loss to approximately $0.02 in profit, and above $0.29 a year earlier. Zacks earnings report
• Positive Sentiment: Profitability and cash generation improved. Operating profit rose 54.8% to $41.3 million, net income reached $42.1 million, and operating cash flow was $33.5 million. Corcept ended the quarter with $111 million in cash and modest capital spending, supporting investment in its pipeline and commercial operations. Quiver Quantitative earnings summary
• Positive Sentiment: Full-year revenue guidance was raised. Management now expects 2026 revenue of $1.1 billion to $1.2 billion, above the approximately $1.0 billion analyst consensus. Executives cited strong momentum in the oncology and Cushing’s syndrome businesses. Corcept second-quarter results
• Neutral Sentiment: Analyst expectations are mixed. Recent price targets range from $72 to $135, with a median of $91.50, indicating considerable disagreement about Corcept’s valuation and growth prospects.
• Negative Sentiment: Wolfe Research downgraded CORT to Underperform. The downgrade creates a near-term counterweight to the earnings beat and higher guidance. Wolfe Research downgrade
• Negative Sentiment: Insider selling remains a concern. Quiver reported 34 insider sales versus two purchases over the past six months, including sales by several executives. In addition, the stock’s very high price-to-earnings ratio leaves it vulnerable if growth or guidance disappoints.

Analysts Set New Price Targets

Several research firms have commented on CORT. Piper Sandler boosted their target price on shares of Corcept Therapeutics from $73.00 to $88.00 and gave the stock an “overweight” rating in a research report on Friday, May 1st. Weiss Ratings reaffirmed a “hold (c-)” rating on shares of Corcept Therapeutics in a research note on Wednesday, June 24th. Wolfe Research cut shares of Corcept Therapeutics from a “peer perform” rating to an “underperform” rating and set a $50.00 price objective for the company. in a report on Monday. HC Wainwright upped their price objective on shares of Corcept Therapeutics from $75.00 to $95.00 and gave the stock a “buy” rating in a report on Tuesday, June 2nd. Finally, Zacks Research upgraded Corcept Therapeutics from a “strong sell” rating to a “hold” rating in a report on Monday, May 4th. One research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $94.67.

Corcept Therapeutics Company Profile

Corcept Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing drugs that modulate the effects of cortisol, a hormone implicated in a range of severe metabolic, oncologic and psychiatric disorders. The company’s scientific platform centers on selectively targeting the glucocorticoid receptor to counteract the harmful consequences of excess cortisol, a strategy designed to address diseases with significant unmet medical needs.

The company’s flagship marketed product, Korlym (mifepristone), is approved in the United States for the treatment of hyperglycemia secondary to Cushing’s syndrome in patients who have type 2 diabetes or glucose intolerance and are not candidates for surgery.